Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Catalyst Pharmaceuticals stock (CPRX)

Buy Catalyst Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Pharmaceuticals employs 167 staff and has a trailing 12-month revenue of around $411.3 million.

Our top picks for where to buy Catalyst Pharmaceuticals stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Catalyst Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CPRX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Catalyst Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Not rated yet
OPTO
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
★★★★★
Stocks, ETFs, Cryptocurrency
$0
$0
4.5%
N/A
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Catalyst Pharmaceuticals stock price (NASDAQ: CPRX)

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

Information last updated 2024-07-12.
Latest market close$16.90
52-week range$11.55 - $17.50
50-day moving average $15.67
200-day moving average $14.73
Wall St. target price$27.29
PE ratio 29.125
Dividend yield N/A (0%)
Earnings per share (TTM) $0.56

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the close of $16.9 from 2024-07-17

1 week (2024-07-11) 3.62%
1 month (2024-06-18) 12.89%
3 months (2024-04-18) 10.17%
6 months (2024-01-18) 14.97%
1 year (2023-07-18) 21.67%
2 years (2022-07-18) 94.93%
3 years (2021-07-16) 203.96%
5 years (2019-07-18) 308.21%

Is Catalyst Pharmaceuticals stock undervalued or overvalued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Catalyst Pharmaceuticals shares trade at around 29x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $114 million.

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM $411.3 million
Operating margin TTM 27.54%
Gross profit TTM $160 million
Return on assets TTM 9.29%
Return on equity TTM 14.55%
Profit margin 15.83%
Book value $4.76
Market Capitalization $1.9 billion

TTM: trailing 12 months

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $11.55 up to $17.495. A popular way to gauge a stock's volatility is its "beta".

CPRX.US volatility(beta: 0.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 0.703. This would suggest that Catalyst Pharmaceuticals's shares are less volatile than average (for this exchange).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Frequently asked questions

What percentage of Catalyst Pharmaceuticals is owned by insiders or institutions?
Currently 6.208% of Catalyst Pharmaceuticals shares are held by insiders and 83.454% by institutions.
How many people work for Catalyst Pharmaceuticals?
Latest data suggests 167 work at Catalyst Pharmaceuticals.
When does the fiscal year end for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals's fiscal year ends in December.
Where is Catalyst Pharmaceuticals based?
Catalyst Pharmaceuticals's address is: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
What is Catalyst Pharmaceuticals's ISIN number?
Catalyst Pharmaceuticals's international securities identification number is: US14888U1016
What is Catalyst Pharmaceuticals's CUSIP number?
Catalyst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14888U101

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site